Skip to content
Triangle logo TriangleGet started
← Full study record

NCT01408043 · OUTCOME

Platelet Recovery in Super Mobilizers and Normal Mobilizers

Etoposide, Filgrastim, and Plerixafor in Improving Stem Cell Mobilization in Treating Patients With Non-Hodgkin Lymphoma · Source last updated 2019-06-14

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
MEAN
Unit
percentage of change
Interval / dispersion
Standard Deviation
Time frame
Up to 28 days post treatment

What was measured

Platelet recovery in participants receiving greater than or equal to 8 and less than 8 x 10\^6 CD34+ cells/kg.

Analysis population: All participants that had some mobilization

Groups in this outcome

Treatment (Stem Cell Supermobilization)

Patients receive etoposide IV over 4 hours on day 0, filgrastim SC QD beginning day 1, and plerixafor SC 15-18 hours prior to apheresis. Patients unable to achieve target collection of \>= 8 x 10\^6 CD34+ cells/kg receive another dose of plerixafor followed by apheresis. Following the second apheresis, patients achieving =\< 2 x 10\^6 CD34+ cells/kg may continue filgrastim with plerixafor and continue collection according to the attending physician. plerixafor: Given SC filgrastim: Given SC etoposide: Given IV leukapheresis: Undergo apheresis

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Treatment (Stem Cell Supermobilization)24

Reported measurements

Supermobilizers

Analysis denominator · Participants

GroupSource count
Treatment (Stem Cell Supermobilization)7
Values in percentage of change · Interval/dispersion: Standard Deviation
GroupValueSpreadLowerUpperComment
Treatment (Stem Cell Supermobilization)20.96.5Not reportedNot reportedNot reported
Normal Mobilizers

Analysis denominator · Participants

GroupSource count
Treatment (Stem Cell Supermobilization)17
Values in percentage of change · Interval/dispersion: Standard Deviation
GroupValueSpreadLowerUpperComment
Treatment (Stem Cell Supermobilization)19.85.6Not reportedNot reportedNot reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        spread
        6.5
        value
        20.9
    denoms
    1. counts
      1. group Id
        OG000
        value
        7
      units
      Participants
    title
    Supermobilizers
  2. categories
    1. measurements
      1. group Id
        OG000
        spread
        5.6
        value
        19.8
    denoms
    1. counts
      1. group Id
        OG000
        value
        17
      units
      Participants
    title
    Normal Mobilizers
denoms
  1. counts
    1. group Id
      OG000
      value
      24
    units
    Participants
description
Platelet recovery in participants receiving greater than or equal to 8 and less than 8 x 10\^6 CD34+ cells/kg.
dispersion Type
Standard Deviation
groups
  1. description
    Patients receive etoposide IV over 4 hours on day 0, filgrastim SC QD beginning day 1, and plerixafor SC 15-18 hours prior to apheresis. Patients unable to achieve target collection of \>= 8 x 10\^6 CD34+ cells/kg receive another dose of plerixafor followed by apheresis. Following the second apheresis, patients achieving =\< 2 x 10\^6 CD34+ cells/kg may continue filgrastim with plerixafor and continue collection according to the attending physician. plerixafor: Given SC filgrastim: Given SC etoposide: Given IV leukapheresis: Undergo apheresis
    id
    OG000
    title
    Treatment (Stem Cell Supermobilization)
param Type
MEAN
population Description
All participants that had some mobilization
reporting Status
POSTED
time Frame
Up to 28 days post treatment
title
Platelet Recovery in Super Mobilizers and Normal Mobilizers
type
SECONDARY
unit Of Measure
percentage of change

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice